Pain management最新文献

Aim: We aimed to evaluate real-world outcomes of peripheral nerve stimulation (PNS) used to treat chronic neuropathic pain (CNP) at a tertiary pain management center.

Methods: Thirty adults who underwent PNS for CNP between June 2015 and September 2021 completed pain and psychosocial assessments in the 6 months before, and 2-3 years after PNS treatment. Pain intensity was measured using the NIH Patient Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Short From (3A). Psychosocial outcomes including depression, anxiety, and sleep disturbance were also measured.

Results: Prior to receiving PNS, long-term responders reported significantly fewer depressive symptoms compared to non-responders (PROMIS depression t-score 50.3 [10.7] vs 57.9 [8.9]; p-value = 0.05). Eleven participants (36.7%) reported long-term treatment response. There was a significantly greater improvement in pain intensity among responders compared to non-responders who reported increased pain (PROMIS Pain Intensity score -9.0 [-4.2] vs. +3.1[+3.2]; p-value < 0.0001).

Conclusions: Patients report clinically meaningful long-term pain relief after receiving PNS through both 60-day and permanent implant systems, with significant reductions in pain intensity observed in long-term responders. Long-term responders reported fewer depressive symptoms compared to non-responders prior to receiving therapy, emphasizing the importance of psychological screening and psychological optimization prior to receiving PNS.

Objectives: To systematically review and conduct a meta-analysis of studies on peripheral magnetic stimulation (PMS) for fibromyalgia (FM) treatment.

Methods: MEDLINE, EMBASE, CENTRAL, CINHAL, Web of Science, and ProQuest databases were searched from inception to July 2023 for studies in adult patients with FM treated with PMS. Studies using transcranial magnetic stimulation were excluded.

Results: Six randomized controlled trials (RCTs) (n = 279 patients) were identified and included in the review. PMS regimens varied, ranging from 8 to 40 min per session over 3-84 days. All studies compared PMS to a visually and physically identical sham device without magnetic fields. Most of the included studies demonstrated positive findings for PMS on pain and functional outcomes. In our meta-analysis, PMS significantly reduced pain scores within 1-3 months (mean difference -1.86 on NRS, 95% confidence interval -2.85 to -0.87, p = 0.0002, I² = 68%, 4 studies [154 participants], low quality of evidence), but not at ≥3 months (low quality of evidence). Minimal adverse effects were reported.

Discussion: Evidence for PMS use in FM is encouraging for short-term benefit. However, heterogeneous patient populations, varied PMS regimens, and limited number of studies are important limitations. Large, high-quality RCTs are needed to confirm PMS benefits and to make definitive recommendations.

Protocol registration: PROSPERO Identifier is CRD42021235164.

Introduction: The QTc prolongation effect of methadone has been extensively studied at higher doses commonly used in opioid dependence maintenance therapy, but evidence remains limited regarding its impact at the lower doses typically prescribed for cancer pain. This study aims to evaluate the effect of oral methadone on QTc intervals in cancer pain patients.

Methods: A retrospective analysis was performed on adult patients initiated on oral methadone therapy for cancer. Pre- and post-methadone QTc intervals, obtained within six months before and between six to twelve months after methadone initiation, respectively, were compared. The proportion of patients with QTc intervals greater than 450 msec and 500 msec before and after methadone therapy were compared.

Results: Among the total of 310 patients, the mean pre-methadone QTc was 384.5 ± 37.8 msec (95% CI 380.3, 388.7) and the mean post-methadone QTc was 388.5 ± 43.4 msec (95% CI 383.6, 393.3). No statistically significant difference in QTc interval was observed (p = 0.1). The proportion of patients with a QTc greater than 450 msec and 500 msec pre- and post-methadone were also not statistically different.

Conclusion: Lower doses of oral methadone for cancer pain do not result in significant QTc prolongation.

Effective pain management has long been hindered by the limitations and risks associated with opioid analgesics, necessitating the exploration of novel, non-opioid alternatives. A comprehensive literature search was conducted using PubMed and Google Scholar during October and November 2024 to identify studies on emerging non-opioid pain management therapeutics. This review evaluates three promising classes of mechanism-specific therapeutics: nerve growth factor (NGF) monoclonal antibodies, transient receptor potential vanilloid 1 (TRPV1) antagonists, and selective sodium channel blockers. By targeting distinct pathways involved in pain sensation, these therapies aim to provide relief for various pain types, including chronic, inflammatory, and neuropathic pain, with potentially fewer side effects. Through a detailed analysis of their mechanisms of action and current evidence, this review highlights the clinical potential of each class, addressing both their efficacy and safety challenges. Ultimately, these emerging therapies represent significant advancements in non-opioid pain management, with the potential to reshape standard approaches to patient care.

Background: The aims of this review were to identify and to analyze the clinical studies that used subcutaneous injections of dextrose for treating musculoskeletal pain, in order to establish an overview.

Methods: A systematic search was carried out in scientific databases including Web of Science, Cochrane Central Register of Controlled Trials, PUBMED and other sources, up until March 2024. We included clinical studies that used subcutaneous injections of dextrose in the treatment of individuals with musculoskeletal pain associated with tendinopathies, enthesopathy, osteoarthritis, ligament sprains, muscle strains or bursitis of various locations.

Results: Twenty studies that met the criteria were included in this review; of those, 13 were randomized clinical trials, one non-randomized comparative study and six were case series studies, comprising a total of 1226 patients. In all included studies, efficacy in pain reduction was reported in the groups treated with dextrose when comparing evaluations at baseline, short term and medium term.

Conclusions: Subcutaneous injections of dextrose could be a beneficial treatment for reducing musculoskeletal pain; however, factors such as the high heterogeneity in the treatment schemes, uncertainty in the mechanisms of action and the level of evidence found, indicate that this technique is still under development.

Aims: Post-mastectomy pain syndrome is a common postoperative complication that can impact patient quality of life and function. The aim of this systematic review is to evaluate the effectiveness of cryoneurolysis as an intervention for the management of post-mastectomy pain.

Methods: A prospero-registered systematic review was performed following PRISMA 2020 guidelines. An initial screening consisted of 53 articles imported from the following databases: PubMed, Embase, Web of Science, Cochrane, and Scopus. Google Scholar and WorldCat were also searched to pull any further articles.

Results: Three clinical trials, one case series, and one case report were included. Primary outcome measure of patient reported pain score (VAS or NRS) showed clinically significant reduction in pain in all five studies. Three of the studies also reported reduction in opioid use with cryoneurolysis intervention. A pooled effect size of Hedges g = -0.963, (95% CI [-1.55, -0.373]), with heterogeneity (I² = 0.70).

Conclusion: Cryoneurolysis intervention shows promising and clinically significant relief in post-mastectomy pain in patients and further studies are encouraged.

Background: Chronic pain management is challenging. Those with chronic pain present to health professionals, including osteopaths.

Methods: Secondary analysis of a cross-sectional survey of the Osteopathy Research Connect - New Zealand (ORC-NZ), a practice-based research network (PBRN). Demographic, practice, and treatment characteristics of osteopaths who 'often' and 'not often' treat chronic pain patients were collected.

Results: Two hundred and seventy-seven (277) NZ osteopaths responded and just over half (50.7% N = 138) reported 'often' treating chronic pain patients. This group, who have a similar male-to-female ratio, often use a diagnostic screening questionnaire (aOR 3.78), and often treat patients with non-musculoskeletal complaints (aOR 3.12) and tendinopathies (aOR 3.41).

Conclusions: This study highlights practice and clinical management characteristics of NZ osteopaths who manage chronic pain patients.

Aims: Phantom limb pain (PLP) is a painful sensation occurring in patients around the site of an amputation. The aim of this systematic review is to evaluate the efficacy of cryoneurolysis in the management of phantom limb pain.

Materials and methods: A systematic review was performed according to the PRISMA 2020 guidelines. An initial search yielded 200 articles from four major scientific databases (PubMed, Embase, Cochrane Library, WebOfScience). Five articles met inclusion criteria, four of which underwent additional pooled statistical analysis.

Results: Pooled analysis of the included trials revealed a cumulative Cohen's d effect size of 1.55 (95% CI [0.24, 2.87]; p = 0.02; z = 2.32) for the reduction of pain on a 10-point pain scale following cryoneurolysis intervention. The remaining article that did not meet inclusion criteria for statistical analysis was a case report that reported a reduction in pain from 9/10 to 1/10 one week following intervention.

Conclusions: The large effect size demonstrated a statistically and clinically significant improvement in patient-reported pain. Additionally, patients may be able to reduce their amount of pharmaceutical pain management with successful cryoneurolysis treatment. However, these findings are limited by the small sample size and high heterogeneity between studies. Further high-quality studies should be performed to corroborate these findings.

Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42024543085.